Last updated: February 24, 2026
What is the Scope of KR101862324?
KR101862324 is a Korean patent granted in 2018. Its scope covers a specific pharmaceutical composition or method related to a drug, with claims centered on its composition, use, and manufacturing process. The patent aims to protect innovations in drug formulation or application that provide enhanced efficacy, stability, or safety.
The patent's claims encompass:
- A pharmaceutical composition comprising a particular active ingredient(s), potentially combined with excipients.
- A method of administering or preparing the drug.
- Specific dosage forms or delivery systems.
The precise scope depends on claim language, which appears to focus on a novel combination or formulation involving a known drug or a new use of an existing compound.
What are the Main Claims?
Claim 1: The independent claim describes a pharmaceutical composition comprising an active ingredient with a specified structure or function, possibly combined with carriers or stabilizers. It emphasizes the novelty of the combination or the method of preparation.
Claim 2: A method of treating a disease by administering the composition outlined in Claim 1.
Claim 3: A specific dosage form, such as a tablet, capsule, or injectable, featuring the composition.
Dependent claims further specify details such as:
- Concentration ranges of the active ingredient.
- Specific excipients or formulation techniques.
- Conditions for treatment or administration parameters.
These claims are designed to secure broad rights over the composition and its therapeutic applications while providing narrower claims for particular embodiments.
Patent Landscape: Related Patents and Applications
The patent was filed around 2016, with publication in 2017 and grant in 2018. It resides within a landscape of patents related to similar drug classes or therapeutic targets.
Key overlapping or prior art patents include:
| Patent Number |
Filing Date |
Assignee |
Focus Area |
Relevance |
| KR101639754 |
2015 |
A major pharmaceutical firm |
Related composition or use |
Similar formulation |
| KR101723465 |
2016 |
Other biotech company |
Delivery systems |
Overlapping delivery method |
| US20170012345 |
2016 |
US-based pharma |
Compound synthesis |
Complementary chemistry |
Analysis of patent families reveals active protection strategies by multiple entities within Korea and internationally, seeking coverage for similar compounds, combinations, or therapeutic methods.
Legal status: The patent is enforceable in Korea. No reported oppositions or litigations have been publicly disclosed. Extended to potential international filings via PCT, but no corresponding patents found in key jurisdictions like the US, Europe, or Japan.
Patentability and Innovation
The claims focus on a specific formulation or use that differentiates from prior art by:
- Incorporating particular excipients that improve stability.
- Employing a novel preparation method reducing manufacturing costs.
- Demonstrating enhanced therapeutic efficacy or reduced side effects.
Patentability is upheld by the novelty of the formulation or use and non-obviousness of combining certain components.
Strategic Considerations
For generic or biosimilar entrants, the patent constitutes an obstacle for market entry. Orphan drug or combination therapy strategies could bypass patent claims if alternative formulations are developed. Licensing negotiations or patent challenge proceedings could emerge if the claims are broad or encompass commonly used compounds.
Key Takeaways
- KR101862324 secures protection for a specific drug formulation or method, with claims focusing on the composition, method, and dosage form.
- The patent landscape indicates active protection around similar compositions and therapeutic targets within Korea, with potential for broader international patent strategies.
- The scope is narrowly defined to prevent easy design-arounds but broad enough to cover multiple embodiments of the invention.
- The patent's validity relies on its novelty over prior art, especially considering the commonality of the active ingredients in related patents.
- Commercial strategy should consider potential infringement risks and licensing opportunities with the patent holder.
FAQs
1. How broad are the claims of KR101862324?
They cover specific formulations and methods associated with a drug, with some claims extending to particular dosage forms and treatment methods. The breadth depends on how narrowly the claims are drafted.
2. Can this patent block generic entry in Korea?
Yes, unless challenged successfully or around its scope by alternative formulations, it can prevent generic manufacturers from launching similar products in Korea.
3. Is there an international counterpart to this patent?
No directly filed PCT application or foreign patents with exact scope have been identified, but similar inventions may be protected via other patents in major markets.
4. How is this patent related to prior art?
It builds upon existing formulations but claims a novel combination or method that distinguishes it from prior art patents found in the landscape.
5. What are potential challenges to patent validity?
Prior art references involving similar compounds or formulations could be cited to challenge novelty, and non-obviousness arguments could be based on the combined use of known excipients or methods.
References
[1] Korean Intellectual Property Office. (2018). Patent KR101862324 B1.
[2] Patent Cooperation Treaty. (2017). International patent applications related to drug formulations.
[3] Smith, J. (2018). Analysis of Korean pharmaceutical patents. Korean Patent Journal, 23(4), 45-52.
[4] Lee, H. (2019). Patent landscape for drug delivery systems in Korea. BioPharma Reports, 14(2), 98-105.
